Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8811478 | 0.93 | ACE2 (0.47) | ACE2TSHRMAPTBLMHDAC1 | |
| SCHEMBL8814041 | 0.91 | ACE2 (0.48) | ACE2MAPTBLMPTPN1NFKB1 | |
| SCHEMBL8812393 | 0.86 | TSHR (0.46) | ACE2TSHRMAPTBLMHDAC1 | |
| SCHEMBL8811537 | 0.84 | ACE2 (0.36) | ACE2MAPTBLMPTPN1NFKB1 | |
| SCHEMBL7741480 | 0.83 | ACE2 (0.55) | ACE2TSHRTDP1PTPN1ALDH1A1 | |
| SCHEMBL8811563 | 0.82 | ACE2 (0.48) | ACE2MAPTBLMCA1CES2 | |
| SCHEMBL14681977 | 0.82 | ACE2 (0.44) | ACE2TSHRMAPTBLMHDAC1 | |
| SCHEMBL1783660 | 0.82 | ACE2 (0.44) | ACE2TSHRMAPTBLMHDAC1 | |
| SCHEMBL4003119 | 0.82 | AKR1B1 (0.52) | ACE2TSHRMAPTHDAC1HDAC2 | |
| SCHEMBL15824535 | 0.80 | ACE2 (0.42) | ACE2TSHRMAPTBLMHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3372581-B1 | FULLERENE DERIVATIVE AND n-TYPE SEMICONDUCTOR MATERIAL | DAIKIN IND LTD (JP) | 2021-06-23 | — | — | EP | disclosed |
| US-10894770-B2 | Fullerene derivative and n-type semiconductor material | DAIKIN INDUSTRIES, LTD. (JP) | 2021-01-19 | — | — | US | disclosed |
| US-20180282274-A1 | FULLERENE DERIVATIVE AND n-TYPE SEMICONDUCTOR MATERIAL | DAIKIN INDUSTRIES, LTD. (JP) | 2018-10-04 | — | — | US | disclosed |
| EP-3372581-A1 | FULLERENE DERIVATIVE AND n-TYPE SEMICONDUCTOR MATERIAL | Daikin Industries, Ltd. (JP) | 2018-09-12 | — | — | EP | disclosed |
| CN-108137498-A | Fullerene derivate and n-type semiconductor | 大金工业株式会社 | 2018-06-08 | — | — | CN | disclosed |
| US-5691319-A | ANTICARCINOGENIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1997-11-25 | — | — | US | disclosed |
| US-5650430-A | Radicicol derivatives, their preparation and their anti-tumor activity | SANKYO COMPANY, LIMITED (JP) | 1997-07-22 | — | — | US | disclosed |
| US-5597846-A | ESTERS OF RADICICOL | SANKYO COMPANY, LIMITED (JP) | 1997-01-28 | — | — | US | disclosed |
| EP-0536936-B1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | SANKYO CO (JP) | 1996-08-14 | — | — | EP | disclosed |
| EP-0536936-A1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | Sankyo Company Limited (JP) | 1993-04-14 | — | — | EP | disclosed |
| WO-1991018905-A1 | RADICICOL DERIVATIVES, THEIR PREPARATION AND THEIR ANTI-TUMOR ACTIVITY | SANKYO COMPANY LIMITED (JP) | 1991-12-12 | — | — | WO | disclosed |
| EP-0460950-A1 | Radicicol derivatives, their preparation and their anti-tumour activity | Sankyo Company Limited (JP) | 1991-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894770-B2 | Fullerene derivative and n-type semiconductor material | SUN2, NES, L1CAM | ACE2 3629/4885TSHR 2875/4885MAPT 3449/4885 |
| US-20180282274-A1 | FULLERENE DERIVATIVE AND n-TYPE SEMICONDUCTOR MATERIAL | SUN2, NES, L1CAM | ACE2 3629/4885TSHR 2875/4885MAPT 3449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.